JP2004182630A - Long-acting muscle fatigue ameliorant - Google Patents
Long-acting muscle fatigue ameliorant Download PDFInfo
- Publication number
- JP2004182630A JP2004182630A JP2002350200A JP2002350200A JP2004182630A JP 2004182630 A JP2004182630 A JP 2004182630A JP 2002350200 A JP2002350200 A JP 2002350200A JP 2002350200 A JP2002350200 A JP 2002350200A JP 2004182630 A JP2004182630 A JP 2004182630A
- Authority
- JP
- Japan
- Prior art keywords
- whey protein
- weight
- parts
- food
- muscle fatigue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010049565 Muscle fatigue Diseases 0.000 title claims abstract description 37
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 81
- 235000021119 whey protein Nutrition 0.000 claims abstract description 80
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 79
- 235000013305 food Nutrition 0.000 claims abstract description 54
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 36
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 34
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 34
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 34
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960000310 isoleucine Drugs 0.000 claims abstract description 34
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000004474 valine Substances 0.000 claims abstract description 34
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 33
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 22
- 235000013361 beverage Nutrition 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 38
- 230000002459 sustained effect Effects 0.000 claims description 23
- 239000003531 protein hydrolysate Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000007857 degradation product Substances 0.000 claims description 8
- 230000002085 persistent effect Effects 0.000 claims description 8
- 230000017854 proteolysis Effects 0.000 claims description 8
- 102000004407 Lactalbumin Human genes 0.000 claims description 5
- 108090000942 Lactalbumin Proteins 0.000 claims description 5
- 102000008192 Lactoglobulins Human genes 0.000 claims description 5
- 108010060630 Lactoglobulins Proteins 0.000 claims description 5
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 5
- 230000003387 muscular Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 34
- 150000001413 amino acids Chemical class 0.000 description 32
- 239000003826 tablet Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 235000008504 concentrate Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 150000005693 branched-chain amino acids Chemical class 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- -1 amino acid compound Chemical class 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000014510 cooky Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- YXAOOTNFFAQIPZ-UHFFFAOYSA-N 1-nitrosonaphthalen-2-ol Chemical compound C1=CC=CC2=C(N=O)C(O)=CC=C21 YXAOOTNFFAQIPZ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical class OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000269908 Platichthys flesus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【０００１】
【発明の属する技術分野】
本発明は、アミノ酸およびホエイ蛋白質成分を含有することを特徴とする医薬品又は飲食品に関する。
【０００２】
【従来の技術】
ロイシン、イソロイシンおよびバリンは、分岐鎖アミノ酸（ＢＣＡＡ）と呼ばれ、その３種アミノ酸の混合物には筋肉疲労回復効果があることが知られている（例えば、特許文献１参照）。ＢＣＡＡの３種混合物は、顆粒状または飲料に加工され栄養剤として広く用いられているが、小腸から直ぐに吸収された後、比較的速やかに代謝されるため、筋肉疲労回復の持続的効果は得られにくい。
【０００３】
また、ホエィ蛋白質またはホエイ蛋白質または大豆蛋白質分解物を含む栄養剤が知られてはいるが、筋肉疲労回復の持続作用については知られていない（例えば、非特許文献１及び非特許文献２参照）。
【０００４】
一方、ＢＣＡＡの３種混合物と、蛋白質の混合物としては、ロイシン、イソロイシンおよびバリンからなるアミノ酸混合物に２〜３０倍量の蛋白質を入れ固体化した組成物（例えば、特許文献２参照）も知られているが、蛋白質を単に賦形剤として使用しているだけで、疲労回復効果の促進のために用いられているわけではない。
【０００５】
【特許文献１】
特開平８−１９８７４８号
【０００６】
【特許文献２】
特開昭６０−１８６２６１号
【０００７】
【非特許文献１】
ガストロエンテロロジー（Ｇａｓｔｒｏｅｎｔｅｒｏｌｏｇｙ）、１９７６年、第７巻、ｐ．１５１−１６１
【０００８】
【非特許文献２】
ガット（Ｇｕｔ）、１９７４年、第１４巻、ｐ．４９４−５０１
【０００９】
【発明が解決しようとする課題】
スポーツ用途に用いるＢＣＡＡ混合物を含む栄養剤は、通常、２〜３ｇ程をゼリー、または顆粒剤の形で１日１回服用すれば良いとされていた。しかしながら、かかる投与方法では、投与直後に効果が生じるものの、血中アミノ酸が経時的に代謝、排泄されてしまうため、持続的な効果が得られなかった。このため、１日１回投与の投与方法に適した持続型の栄養組成物の出現が望まれている。もちろん、スポーツ用途以外、例えば、保健、健康維持、日常生活における疲労の回復といった用途においても同様である。
【００１０】
【課題を解決するための手段】
本発明は、上記した当業界の要請に応える目的でなされたものであって、本発明者らは各方面から広範に検討を行い、ＢＣＡＡに更に他の成分を配合する必要性にはじめて着目し、莫大な各種成分の内、アミノ酸に着目しただけでなく、アミノ酸とは別の成分も配合する必要を認めた。そして、本発明者らは、数多くのアミノ酸の内、グルタミンに着目し、また、他の成分として、ホエイ蛋白質成分にはじめて着目した。
【００１１】
そこで、本発明者らは、ＢＣＡＡ混合物の配合組成に関して、ＢＣＡＡ混合物にグルタミンおよびホエイ蛋白質成分を配合し、その組成を鋭意検討した結果、筋肉疲労回復効果が持続することを発見し、本発明を完成するに至った。
【００１２】
本発明は、ロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分を含有することを特徴とする持続性筋肉疲労改善剤に関するものであり、本発明は医薬品及び飲食品のいずれとしても利用することができるので、本発明は、持続性筋肉疲労改善のための飲食品用又は医療用の剤又は持続性筋肉疲労改善用飲食品を提供することができる。
【００１３】
本発明は、上記した４種アミノ酸とホエイ蛋白質成分を含有する剤又は飲食品に関するものであるが、これらを有効成分として含有する剤又は飲食品、及び、これらのみを含有する剤のいずれをも包含するものである。
【００１４】
前者においては、通常、４種アミノ酸がそれぞれ純粋な各アミノ酸化合物として独立して存在すればよく、他のアミノ酸、持続性筋肉疲労改善成分、飲食品、ペプチド等が併用されてもかまわないし、あるいは、４種アミノ酸としては、各アミノ酸の含有量が明らかな場合には、純粋のアミノ酸ではなく、その混合物ないし含有物（例えば、ペプチド、同分解物、食品類等）を使用することができるし、あるいは、これらを併用して、純粋アミノ酸とその混合物を所望する割合で併用することも可能である。また、ホエイ蛋白質成分も同様であって、純粋なもの及び／又はその含有物（混合物）も使用可能である。
【００１５】
後者においては、４種アミノ酸としては純粋な４種のアミノ酸化合物のみが使用され、他のアミノ酸、ペプチド、同分解物、食品その他持続性筋肉疲労改善成分の併用は含まれない。ホエイ蛋白質成分の場合も同様である。
【００１６】
すなわち本発明は、純粋な４種アミノ酸とホエイ蛋白質成分のみを含み他の持続性筋肉疲労改善成分は含まない剤と、これらのほかに他の飲食品や他の成分を併用したり、あるいはこれを含有する成分を使用する剤又は飲食品、すなわちこれらを有効成分として含有する剤又は飲食品の双方を包含するものである。もちろん、前者の場合、製剤に必要な補助剤やドリンクにするための水といった持続性筋肉疲労改善成分ではないものの使用を防げるものではない。
【００１７】
本発明において、ホエイ蛋白質成分としては、ホエイ蛋白質及び／又はホエイ蛋白質分解物が使用され、前者としては、ホエイ蛋白質分離物（Ｗｈｅｙ Ｐｒｏｔｅｉｎ Ｉｓｏｌａｔｅ、ＷＰＩ）やホエイ蛋白質濃縮物（Ｗｈｅｙ Ｐｒｏｔｅｉｌｎ Ｃｏｎｃｅｎｔｒａｔｅ、ＷＰＣ）、α−ラクトアルブミン濃縮物及びβ−ラクトグロブリン濃縮物、後者としては、これらの加水分解物があげられ、これらが１種又は２種以上使用される。
【００１８】
ＷＰＣは、チーズやカゼインを製造する際に生じるホエイを限外濾過・ゲル濾過・乳糖結晶分離などの方法で処理し、蛋白質含量を通常３５〜８５％（固形分換算）まで高めたものである。
【００１９】
ＷＰＩは、ＷＰＣと区別されるものであって、イオン交換法などの方法で蛋白質含量を９５％（固形分換算）程度まで高めたものである。
【００２０】
α−ラクトアルブミン濃縮物、β−ラクトグロブリン濃縮物は、ＷＰＩやＷＰＣから特公平３−６０４６８号などに記載の公知の方法により、分画、濃縮して得ることができる。
【００２１】
加水分解物は特開平６−３４３４２２号に記載のように、バチルス属由来のプロテアーゼ、放線菌由来のプロテアーゼ、トリプシン、キモトリプシンなどにより加水分解して得る、など公知の方法で得たものであって一般の飲食品用に用いられるペプチドであればどのようなものでも良い。
【００２２】
また、ホエイ蛋白質成分は、前記ホエイ蛋白質単独或いはホエイ蛋白質分解物単独のみならず、両者の混合物であっても良く、好ましくはホエイ蛋白質分解物が用いられる。
【００２３】
本発明におけるロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分の組成比としては、ロイシン１０〜３０重量部、イソロイシン５〜１５重量部、バリン５〜１５重量部、グルタミン５〜１５重量部及びホエイ蛋白質成分７５〜２５重量部、好ましくはロイシン１６〜２４重量部、イソロイシン８〜１２重量部、バリン８〜１２重量部、グルタミン８〜１２重量部及びホエイ蛋白質成分６０〜４０重量部、とりわけ好ましくは、ロイシン２０重量部、イソロイシン１０重量部、バリン１０重量部、グルタミン１０重量部及びホエイ蛋白質成分（例えばホエイ蛋白質分解物）５０重量部があげられる。また、ロイシン、イソロイシン、バリンおよびグルタミンとホエイ蛋白質成分との組成は、ロイシン、イソロイシン、バリンおよびグルタミン２５〜７５重量部に対してホエイ蛋白質成分７５〜２５重量部、好ましくはロイシン、イソロイシン、バリンおよびグルタミン４０〜６０重量部に対してホエイ蛋白質成分６０〜４０重量部である。とりわけ好ましくは、ロイシン、イソロイシン、バリン及びグルタミン５０重量部に対してホエイ蛋白質成分５０重量部である。
なお、ホエイ蛋白質成分の重量部は、ＷＰＩやＷＰＣなどのホエイ蛋白質成分に含まれる正味のホエイ蛋白質及び／又はそのホエイ蛋白質分解物を云う（以下においても同じ）。
【００２４】
既述のように本発明は、持続性筋肉疲労改善成分として４種のアミノ酸のみを使用する場合、及び、４種のアミノ酸を有効成分として含有する場合（すなわち、他の成分があってもかまわない場合）の双方を広く包含するものである。したがって、前記ロイシン、イソロイシン、バリンおよびグルタミンの組成比において、その重量は、食品用途または医薬用途用の純粋なアミノ酸の添加量であっても、食品用途または医薬用途用の純粋なアミノ酸の添加量にペプチド分解物中に存在するアミノ酸単量体を加えたものであっても良いが、食品用途または医薬用途用の純粋なアミノ酸の添加量で組成を決定した方が、成分組成が一定のものに調製しやすいので好ましい。ホエイ蛋白質成分の場合も同様である。
【００２５】
本発明は、持続性筋肉疲労改善成分としてロイシン、イソロイシン、バリン、グルタミンの４種アミノ酸及びホエイ蛋白質成分のみを含有する持続性筋肉疲労改善のための飲食品用の剤又は医療用の剤、あるいは、これらを有効成分として含有する持続性筋肉疲労改善のための飲食品用又は医療用の剤又は持続性筋肉疲労改善用飲食品を提供するものであり、本発明において、ロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分のみをあるいはこれらを有効成分として含有することを特徴とする持続性筋肉疲労改善のための飲食品用若しくは医療用の剤又は持続性筋肉疲労改善用飲食品とは、筋肉疲労の予防または治療に用いることのできる飲食品または医薬品であればどのようなものでも良い。
【００２６】
飲食品の種類としては、健康食品（特定保健用食品、栄養機能食品、スポーツ用飲食品等を含む。）として販売される錠剤、カプセル剤、液剤等の栄養組成物、ジュース類、清涼飲料水、茶類、乳酸菌飲料、醗酵乳、乳製品（加工乳、脱脂乳等）、菓子類（アメ、ドロップ、チョコレート、ゼリー、ビスケット、クッキー、アイスクリーム等）が例示できるが、筋肉疲労回復効果を期待する場合は、ロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分を有効量含む健康食品として経口的に用いることが好ましく、医薬品として用いる場合も、例えば錠剤、カプセル剤、シロップ剤、舌下錠等の経口剤が好ましい。
【００２７】
したがって、持続性筋肉疲労改善用飲食品としては、上記した飲食品をすべて包含するものである。また、本発明に係る飲食品用の剤は、錠剤、カプセル剤、液剤等に製剤化したものや、サプリメントやドリンク剤等医薬品に類似した剤型に製剤化したもののほか、上記に例示した通常の飲食品のうち製剤化されたものもすべて包含するものである。医療用の剤としては、常法にしたがって医薬品に製剤化したものがすべて包含されるものである。
【００２８】
健康食品または医薬品に経口的に投与する剤形の製剤化には通常知られた方法が適用され、例えば、各種の賦形剤、滑沢剤、結合剤、崩壊剤、懸濁化剤、等張化剤、乳化剤等を含有していてもよい。
【００２９】
使用する製剤用担体としては、例えば、水、注射用蒸留氷、生理食塩水、グルコース、白糖、マンニット、ラクトース、マンニトール、ソルビトール、ラクチトール、キシリトール、エリスリトール、でん粉、セルロース、メチルセルロース、カルボキシメチルセルロース、ヒドロキシプロピルセルロース、アルギン酸、タルク、クエン酸、炭酸カルシウム、リン酸水素カルシウム、ステアリン酸マグネシウム、尿素、シリコーン樹脂、ソルビタン脂肪酸エステル、グリセリン酸エステル等があげられる。
【００３０】
本発明におけるロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分は、製剤または飲食品１ｇ当たり１〜１０００ｍｇ、好ましくは１０〜９００ｍｇ、とりわけ好ましくは１００〜８００ｍｇ含有することができる。
【００３１】
摂取量及び摂取回数は、投与形態、年齢、体重、症状等により異なるが、４種アミノ酸及びホエイ蛋白質成分として、通常、経口で０．５〜４ｇ、好ましくは１〜３ｇ、とりわけ好ましく２〜３ｇが適当であり、例えばロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分を５００ｍｇ含む錠剤においては１回２〜３錠を１日２回摂取することが好ましい。なお、４種アミノ酸及びホエイ蛋白質分解物（後記するＡＡｓ＋Ｐ）を０．５ｇ／体重１００ｇあたり（１０週齢のＳＤ系雄性ラット）１日１回経口投与したが、１ヶ月経過後も死亡例は認められなかった。
【００３２】
本発明を健康食品以外の食品に用いる場合の調製方法は、ロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分を添加する以外は通常の飲食品の場合と同様である。例えば、飲料または錠剤はロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分に各種添加剤を、必要により適当量の水に溶解して調製することができる。また、食品として、例えばアメ、ドロップ、チョコレート、ゼリー、ビスケット、クッキー等の菓子類は、常法に従い、ロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分を加え、必要な添加剤、さらに必要により適当な担体、例えば小麦粉、米粉、澱粉、コーンスターチ、大豆等を用い、適宜の形態に賦形して調製することができる。
【００３３】
以下に、ロイシン、イソロイシン、バリン、グルタミン及びホエイ蛋白質成分を加えた組成物（以下、ＫＡＡＭと言う）の筋肉疲労の予防および／または改善効果を示す試験例、並びに本発明の予防または治療剤、食品、飲料および医薬品の配合例を示す実施例をあげて、本発明をさらに具体的に説明するが、本発明はこれらの具体例によって制限されるものではない。
【００３４】
【実施例】
（試験例１：ＫＡＡＭの運動後の筋蛋白分解に及ぼす影響）
オスの３週齢のＳＤ系ラットを以下の３群（ｎ＝１５）にわけて使用した。
Ｖｅｈｉｃｌｅ群には、蒸留水を３０ｍｌ／ｋｇ体重となるよう経口投与した。
ＡＡｓ群には、ロイシン：イソロイシン：バリン：グルタミン（２：１：１：１、重量比）の混合物溶液（混合物濃度は１ｇ／３０ｍｌ蒸留水）を調製し、３０ｍｌ／ｋｇ体重となるように経口投与した（混合物としての投与量は１ｇ／ｋｇ体重）。
ＡＡｓ＋Ｐ群には、ロイシン：イソロイシン：バリン、グルタミン：ホエイ蛋白質分解物（２：１：１：１：５、重量比）の混合物溶液（混合物濃度は１ｇ／３０ｍｌ蒸留水）を調製し、３０ｍｌ／ｋｇ体重となるように経口投与した（混合物としての投与量は１ｇ／ｋｇ体重）。
【００３５】
ホエイ蛋白質分解物は、以下の方法により製造したものを用いた。
ＷＰＩ（蛋白質含量９２％）１０００ｇを水８８００ｇに溶解した。ビオプラーゼ（ナガセ生化学工業社）２２００単位／ｇ蛋白質、トリプシン（ノボ社）１３００単位／ｇ蛋白質、キモトリプシン（ノボ社）９０単位／ｇ蛋白質及びアクチナーゼ（科研ファルマ社）１１００単位／ｇ蛋白質を添加し、１０％水酸化ナトリウム溶液でｐＨ７．５に調整しながら５０℃で２０時間加水分解した。これを分画分子量２００００の限外濾過膜で限外濾過して酵素と不溶性の加水分解物を除去した。さらに電気透析装置を用いて電気伝導度が１／１０となるまで脱塩した後乾燥してホエイ蛋白質分解物（蛋白質分解物含量９４％）を得た。
【００３６】
各群を３日間の予備飼育の後、トレッドミルに馴化させるため、１日１回の運動（傾斜６度、スピード７〜２５ｍ／分、３０分間）を３日間行った。１８時間の絶食及び１時間の絶水の後、１時間のトレッドミル運動（傾斜６度、スピード１５〜３０ｍ／分、３０分間）を行った。運動直後に各群に上記したように蒸留水、アミノ酸混合物溶液またはアミノ酸およびホエイ蛋白質分解物混合物溶液（３０ｍｌ／ｋｇ体重、アミノ酸等の投与量としては１ｇ／ｋｇ体重）を経口投与し、投与６時間後に各群５匹を解剖し、両足よりヒラメ筋を摘出し、９５％ＣＯ２−５％０２ガス通気下のクレブスヘンゼレイト重炭酸緩衝液中で２時間半のインキュベーションを行った。ヒラメ筋漿蛋白分解速度の指標としてＴｙｒ（チロシン）放出速度を測定した。一方、上記３群とは別に、運動および投与を行わない以外は上記３群と同様の方法で、ラット１５匹について、０時間目のＴｙｒ放出速度を測定し、これを非運動群のＴｙｒ放出速度とした。
【００３７】
、非運動群、Ｖｅｈｉｃｌｅ群、ＡＡｓ群およびＡＡｓ＋Ｐ群のそれぞれのＴｙｒ放出速度を第１表に示す。
【００３８】
【表１】
【００３９】
その結果、第１表に示すようにヒラメ筋漿蛋白分解速度の指標であるヒラメ筋からのＴｙｒ放出速度は６時間目においてＡＡｓ＋Ｐ群はＶｅｈｉｃｌｅ群に比べ有意（Ｓｔｕｄｅｎｔ‘ｓ ｔ−ｔｅｓｔ、Ｐ ｖａｌｕｅ＜０．０５）に低下したが、ＡＡｓ群とＶｅｈｉｃｌｅ群の間に有意差はなかつた。
【００４０】
また、ＡＡｓ群のＴｙｒ放出速度は、非運動群のＴｙｒ放出速度とほぼ同程度であるのに対し、ＡＡｓ＋Ｐ群のＴｙｒ放出速度は、非運動群のＴｙｒ放出速度より低く保たれており、ＡＡｓ＋Ｐ群では放出効果が明らかに持続していた。
なお、Ｔｙｒ量はＷａａｌｋｅｓらの１−ニトロソ−２−ナフトールを用いる蛍光法（Ｔ．Ｐ．Ｗａａｌｋｅｓ，Ｓ．Ｕｄｅｎｆｒｉｅｎｄ，Ｊ．Ｌａｂ．Ｃｌｉｎ．Ｍｅｄ．５０，７３３（１９５７））によって測定した。
【００４１】
以上、ホエイ蛋白質分解物を加えた本発明においては、運動後の筋肉蛋白分解が持続的に抑制されることが確認された。なお、ホエイ蛋白質分解物にかえてＷＰＩを用いた場合も同様の作用が確認された。
【００４２】
（実施例１）
整粒したロイシン６００ｇ、イソロイシン３００ｇ、バリン３００ｇ、グルタミン３００ｇおよび試験例１で用いたホエイ蛋白質分解物１５００ｇからなるアミノ酸栄養成分混合物にエリスリトール１３７５ｇ、ショ糖脂肪酸エステル５０ｇ、クエン酸３５０ｇおよび香料１２５ｇを加え混合した。
【００４３】
次に直径１３ｍｍの平面杵を装着したロータリー型打錠機（商品名：ＡＰ−１５型、畑鉄工所製）を用い、１錠中ＫＡＡＭ５００ｍｇを含む錠剤を製造した（以下、錠剤１という）。
【００４４】
（実施例２）
整粒したロイシン６００ｇ、イソロイシン３００ｇ、バリン３００ｇ、グルタミン３００ｇおよび試験例１で用いたホエイ蛋白質分解物１２００ｇからなるアミノ酸栄養成分混合物とエリスリトール１３７５ｇとを配合したものを流動層造粒乾燥機（グラット社製ＷＳＧ−５型）に投入し、マルトース１００ｇを精製水１５００ｇに溶解した結合剤液を噴霧し造粒物を得た。得られた造粒乾燥物３６６０ｇにショ糖脂肪酸エステル４０ｇを加え打錠用顆粒とした。
【００４５】
次に、直径１５ｍｍの平面杵を装着したロータリ型打錠機（商品名：ＡＰ−１５型、畑鉄工所製）を用い圧縮成型し、１錠中ＫＡＡＭ４５０ｍｇを含む錠剤を製造した（以下、錠剤２という）。同様にして、ＷＰＣ、β−ラクトグロブリン濃縮物、α−ラクトアルブミン濃縮物の加水分解物を用いて、錠剤（錠剤３、４、５）をそれぞれ製造した。
【００４６】
（実施例３）
ロイシン２．０ｇ、イソロイシン１．０ｇ、バリン１．０ｇ、グルタミン１．０ｇ、試験例１で用いたホエイ蛋白質分解物４．０ｇ、大豆蛋白１３．５ｇ、キトサン２．５ｇ、アルギニン１．５ｇ、カフェイン０．０５ｇ、小麦粉８５．０ｇ、ショートニング５０．０ｇ、グラニュー糖５５．０ｇ、ベーキングパウダー１．５ｇに水２０．０ｇを加えて、混練して生地を調製し、成型した後、常法により焼成して、クッキーを製造した。
【００４７】
【発明の効果】
本発明により、筋肉疲労に対して持続的な回復効果を示すアミノ酸栄養組成物が提供される。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a pharmaceutical product or a food or drink, comprising an amino acid and a whey protein component.
[0002]
[Prior art]
Leucine, isoleucine and valine are called branched-chain amino acids (BCAA), and it is known that a mixture of these three amino acids has a muscle fatigue recovery effect (for example, see Patent Document 1). The BCAA triad is processed into granules or beverages and is widely used as a nutritional supplement. However, it is absorbed quickly from the small intestine and is metabolized relatively quickly. It is hard to be.
[0003]
In addition, nutrients containing whey protein or whey protein or soybean protein decomposed product are known, but a sustained action of recovery from muscle fatigue is not known (for example, see Non-Patent Documents 1 and 2). .
[0004]
On the other hand, as a mixture of three kinds of BCAAs and a protein, a composition obtained by solidifying 2 to 30 times the amount of protein in an amino acid mixture consisting of leucine, isoleucine and valine (for example, see Patent Document 2) However, the protein is merely used as an excipient, and is not used to promote the effect of recovering from fatigue.
[0005]
[Patent Document 1]
JP-A-8-198748
[Patent Document 2]
JP-A-60-186261
[Non-patent document 1]
Gastroenterology, 1976, Vol. 7, p. 151-161
[0008]
[Non-patent document 2]
Gut, 1974, Vol. 14, p. 494-501
[0009]
[Problems to be solved by the invention]
It has been said that a nutritional supplement containing a BCAA mixture used for sports purposes usually needs to be taken once or twice a day in the form of jelly or granules. However, although such an administration method produces an effect immediately after administration, amino acids in the blood are metabolized and excreted with time, so that a sustained effect cannot be obtained. Therefore, the appearance of a sustained-type nutritional composition suitable for a once-a-day administration method is desired. Of course, the same applies to uses other than sports, such as health, health maintenance, and recovery from fatigue in daily life.
[0010]
[Means for Solving the Problems]
The present invention has been made for the purpose of responding to the demands of the above-mentioned industry, and the present inventors have conducted extensive studies from various fields and focused on the necessity of further blending other components with BCAA for the first time. Among the enormous various components, not only focused on amino acids, but also recognized the need to mix components other than amino acids. Then, the present inventors focused on glutamine among many amino acids, and for the first time focused on whey protein components as other components.
[0011]
Therefore, the present inventors have found that the glutamine and whey protein components are blended in the BCAA mixture with respect to the composition of the BCAA mixture, and as a result of intensive study of the composition, they have found that the muscle fatigue recovery effect is sustained. It was completed.
[0012]
The present invention relates to a sustained muscle fatigue improving agent characterized by containing leucine, isoleucine, valine, glutamine and whey protein components, and the present invention can be used as any of pharmaceuticals and foods and drinks Therefore, the present invention can provide a food or drink or medical agent for improving sustained muscle fatigue or a food or drink for improving sustained muscle fatigue.
[0013]
The present invention relates to an agent or a food or drink containing the above-mentioned four amino acids and a whey protein component, and includes an agent or a food or drink containing these as an active ingredient, and an agent or a food or drink containing only these. Includes
[0014]
In the former, usually, the four amino acids may be each independently present as a pure amino acid compound, and other amino acids, sustained muscle fatigue improving ingredients, foods and drinks, peptides and the like may be used in combination, or As the four amino acids, when the content of each amino acid is clear, not a pure amino acid but a mixture or a content thereof (eg, a peptide, the same degradation product, foods, etc.) can be used. Alternatively, a pure amino acid and a mixture thereof can be used in a desired ratio in combination with each other. The same applies to the whey protein component, and a pure substance and / or a substance (mixture) thereof can be used.
[0015]
In the latter, only four pure amino acid compounds are used as the four amino acids, and other amino acids, peptides, degradation products, foods, and other combinations of sustained muscle fatigue improving components are not included. The same applies to whey protein components.
[0016]
That is, the present invention relates to an agent containing only pure four amino acids and a whey protein component and not containing any other sustained muscle fatigue improving component, in addition to these, other foods and drinks and other components, or Or foods and drinks and foods using the ingredient containing the compound, that is, both agents and foods and drinks containing these as an active ingredient. Of course, in the former case, the use of non-sustained muscle fatigue-improving components such as supplements necessary for the preparation and water for making a drink cannot be prevented.
[0017]
In the present invention, whey protein and / or whey protein hydrolyzate is used as the whey protein component, and the former includes whey protein isolate (Whey Protein Isolate, WPI) and whey protein concentrate (Whey Protein Concentrate, WPC). , Α-lactalbumin concentrate and β-lactoglobulin concentrate, and the latter include hydrolysates thereof, and one or more of them are used.
[0018]
WPC is obtained by treating whey produced at the time of producing cheese or casein by a method such as ultrafiltration, gel filtration, or lactose crystal separation to increase the protein content to 35 to 85% (in terms of solid content). .
[0019]
WPI is distinguished from WPC in that the protein content is increased to about 95% (in terms of solid content) by a method such as an ion exchange method.
[0020]
The α-lactalbumin concentrate and β-lactoglobulin concentrate can be obtained by fractionation and concentration from WPI or WPC by a known method described in Japanese Patent Publication No. 3-60468.
[0021]
The hydrolyzate is obtained by a known method, for example, as described in JP-A-6-343422, obtained by hydrolyzing with a Bacillus-derived protease, an actinomycete-derived protease, trypsin, chymotrypsin, or the like. Any peptide may be used as long as it is used for general food and drink.
[0022]
In addition, the whey protein component may be not only the whey protein alone or the whey protein degradation product alone, but also a mixture of both, and preferably, the whey protein degradation product is used.
[0023]
The composition ratio of leucine, isoleucine, valine, glutamine and whey protein components in the present invention is as follows: leucine 10-30 parts by weight, isoleucine 5-15 parts by weight, valine 5-15 parts by weight, glutamine 5-15 parts by weight and whey protein 75 to 25 parts by weight of components, preferably 16 to 24 parts by weight of leucine, 8 to 12 parts by weight of isoleucine, 8 to 12 parts by weight of valine, 8 to 12 parts by weight of glutamine and 60 to 40 parts by weight of whey protein component, particularly preferably Examples include 20 parts by weight of leucine, 10 parts by weight of isoleucine, 10 parts by weight of valine, 10 parts by weight of glutamine, and 50 parts by weight of a whey protein component (for example, a whey protein hydrolyzate). Further, the composition of leucine, isoleucine, valine and glutamine and the whey protein component is such that leucine, isoleucine, valine and glutamine are 25 to 75 parts by weight and whey protein component is 75 to 25 parts by weight, preferably leucine, isoleucine, valine and It is 60 to 40 parts by weight of whey protein component based on 40 to 60 parts by weight of glutamine. Particularly preferably, the whey protein component is 50 parts by weight based on 50 parts by weight of leucine, isoleucine, valine and glutamine.
The parts by weight of the whey protein component refers to the net whey protein contained in the whey protein component such as WPI or WPC and / or its degradation product (the same applies to the following description).
[0024]
As described above, the present invention relates to a case where only four kinds of amino acids are used as a sustained muscle fatigue improving component and a case where four kinds of amino acids are contained as an active ingredient (that is, even if other ingredients are present). If not present). Therefore, in the composition ratio of leucine, isoleucine, valine and glutamine, the weight is the amount of pure amino acid for food use or pharmaceutical use, even if it is the amount of pure amino acid for food use or pharmaceutical use. The amino acid monomer present in the peptide degradation product may be added to the product, but it is better to determine the composition based on the amount of pure amino acid added for food use or pharmaceutical use, and that the component composition is constant It is preferable because it can be easily prepared. The same applies to whey protein components.
[0025]
The present invention provides a food or drink agent or a medical agent for sustained muscle fatigue improvement containing only four amino acids of leucine, isoleucine, valine, and glutamine as a sustained muscle fatigue improving component and a whey protein component, or It is intended to provide a food or drink agent for improving sustained muscle fatigue or a food or drink for improving persistent muscle fatigue containing these as an active ingredient, and in the present invention, leucine, isoleucine, valine, Glutamine and whey protein components alone or containing them as active ingredients are used as food or drink or medical agents for sustained muscle fatigue improvement or foods and drinks for sustained muscle fatigue improvement. Any foods, drinks, or pharmaceuticals that can be used for the prevention or treatment of the disease may be used.
[0026]
The types of foods and drinks include nutritional compositions such as tablets, capsules, and liquids sold as health foods (including foods for specified health use, nutritional functional foods, sports foods and drinks, etc.), juices, and soft drinks. , Lactobacillus drinks, fermented milk, dairy products (processed milk, skim milk, etc.), and confectionery (candy, drops, chocolate, jelly, biscuits, cookies, ice cream, etc.). If expected, it is preferable to use it orally as a health food containing an effective amount of leucine, isoleucine, valine, glutamine and whey protein components, and when used as a pharmaceutical, for example, tablets, capsules, syrups, sublingual tablets, etc. Are preferred.
[0027]
Therefore, the food and drink for improving sustained muscle fatigue include all of the above food and drink. In addition, the food and beverage preparations according to the present invention include tablets, capsules, liquid preparations and the like, and preparations similar to pharmaceutical preparations such as supplements and drinks, as well as the above-mentioned usual preparations. Of all foods and beverages of the present invention. Medical agents include all those formulated into pharmaceuticals in accordance with ordinary methods.
[0028]
For the preparation of a dosage form for oral administration to health foods or pharmaceuticals, generally known methods are applied, for example, various excipients, lubricants, binders, disintegrants, suspending agents, etc. It may contain a toning agent, an emulsifier and the like.
[0029]
Pharmaceutical carriers used include, for example, water, distilled ice for injection, physiological saline, glucose, sucrose, mannitol, lactose, mannitol, sorbitol, lactitol, xylitol, erythritol, starch, cellulose, methylcellulose, carboxymethylcellulose, hydroxy Examples include propylcellulose, alginic acid, talc, citric acid, calcium carbonate, calcium hydrogen phosphate, magnesium stearate, urea, silicone resins, sorbitan fatty acid esters, and glyceric acid esters.
[0030]
The leucine, isoleucine, valine, glutamine and whey protein components in the present invention can be contained in an amount of 1 to 1000 mg, preferably 10 to 900 mg, particularly preferably 100 to 800 mg per 1 g of a preparation or food or drink.
[0031]
The amount of intake and the number of intakes vary depending on the administration form, age, body weight, symptoms, etc., but are usually 0.5 to 4 g, preferably 1 to 3 g, particularly preferably 2 to 3 g orally as four amino acids and whey protein components. For example, in the case of tablets containing 500 mg of leucine, isoleucine, valine, glutamine and whey protein components, it is preferable to take 2-3 tablets at a time, twice a day. In addition, four kinds of amino acids and a whey protein hydrolyzate (AAs + P described later) were orally administered once a day per 0.5 g / 100 g of body weight (10-week-old male SD rats). I was not able to admit.
[0032]
The preparation method when the present invention is used for foods other than health foods is the same as that for ordinary foods and drinks except that leucine, isoleucine, valine, glutamine and whey protein components are added. For example, beverages or tablets can be prepared by dissolving various additives in leucine, isoleucine, valine, glutamine, and whey protein components, if necessary, in an appropriate amount of water. As foods, for example, sweets such as candy, drops, chocolates, jellies, biscuits, cookies, etc. may be prepared by adding leucine, isoleucine, valine, glutamine and whey protein components according to a conventional method, adding necessary additives, and further, if necessary. It can be prepared by using a suitable carrier, for example, wheat flour, rice flour, starch, corn starch, soybean and the like, and shaping into an appropriate form.
[0033]
Hereinafter, a test example showing a preventive and / or ameliorating effect on muscle fatigue of a composition containing leucine, isoleucine, valine, glutamine and whey protein components (hereinafter referred to as KAAM), and a prophylactic or therapeutic agent of the present invention, The present invention will be described more specifically with reference to examples showing examples of blending foods, beverages, and pharmaceuticals, but the present invention is not limited to these specific examples.
[0034]
【Example】
(Test Example 1: Effect of KAAM on muscle protein degradation after exercise)
Male 3-week-old SD rats were used in the following three groups (n = 15).
To the Vehicle group, distilled water was orally administered to give 30 ml / kg body weight.
For the AAs group, a mixture solution of leucine: isoleucine: valine: glutamine (2: 1: 1: 1, weight ratio) (mixture concentration: 1 g / 30 ml distilled water) was prepared, and was orally adjusted to 30 ml / kg body weight. (The dose as a mixture is 1 g / kg body weight).
For the AAs + P group, a mixture solution of leucine: isoleucine: valine, glutamine: whey protein hydrolyzate (2: 1: 1: 1: 5, weight ratio) (mixture concentration: 1 g / 30 ml distilled water) was prepared, and 30 ml / Oral administration was performed to give a body weight of 1 kg (the dose as a mixture was 1 g / kg body weight).
[0035]
The whey protein hydrolyzate used was produced by the following method.
1000 g of WPI (protein content 92%) was dissolved in 8800 g of water. Add 2200 units / g protein of bioprase (Nagase Seikagaku), 1300 units / g protein of trypsin (Novo), 90 units / g of chymotrypsin (Novo) and 1100 units / g of actinase (Kaken Pharma). The mixture was hydrolyzed at 50 ° C. for 20 hours while adjusting the pH to 7.5 with a 10% sodium hydroxide solution. This was subjected to ultrafiltration with an ultrafiltration membrane having a molecular weight cut-off of 20,000 to remove the insoluble hydrolyzate from the enzyme. Further, the product was desalted using an electrodialyzer until the electric conductivity was reduced to 1/10, and then dried to obtain a whey protein hydrolyzate (protein hydrolyzate content 94%).
[0036]
After preliminary breeding of each group for 3 days, a daily exercise (inclination of 6 degrees, speed of 7 to 25 m / min, 30 minutes) was performed for 3 days to acclimate to the treadmill. After 18 hours of fasting and one hour of water deprivation, a one hour treadmill exercise (tilt 6 degrees, speed 15-30 m / min, 30 minutes) was performed. Immediately after exercise, each group was orally administered with distilled water, an amino acid mixture solution or an amino acid and whey protein hydrolyzate mixture solution (30 ml / kg body weight, 1 g / kg body weight as the dose of amino acids, etc.) as described above. were dissected 5 mice each time later, was excised soleus muscle from both legs, the incubation of 2 hours was carried out in Krebs Heng peptidase late bicarbonate buffer at 0 2 gas vent 95% CO 2 -5%. The Tyr (tyrosine) release rate was measured as an indicator of the flounder muscle plasma protein degradation rate. On the other hand, apart from the above three groups, the Tyr release rate at time 0 was measured for 15 rats in the same manner as in the above three groups except that exercise and administration were not performed. Speed.
[0037]
Table 1 shows the Tyr release rates of the non-exercise group, the Vehicle group, the AAs group, and the AAs + P group.
[0038]
[Table 1]
[0039]
As a result, as shown in Table 1, the Tyr release rate from soleus muscle, which is an index of soleus muscle plasma protein degradation rate, was significantly higher at 6 hours in the AAs + P group than in the Vehicle group (Student's t-test, P value). <0.05), but there was no significant difference between the AAs group and the Vehicle group.
[0040]
The Tyr release rate of the AAs group is almost the same as the Tyr release rate of the non-exercise group, whereas the Tyr release rate of the AAs + P group is kept lower than the Tyr release rate of the non-exercise group. The release effect was clearly sustained in the group.
The amount of Tyr was measured by a fluorescence method using 1-nitroso-2-naphthol of Waalkes et al. (TP Waalkes, S. Udenfriend, J. Lab. Clin. Med. 50, 733 (1957)).
[0041]
As described above, in the present invention to which whey protein hydrolyzate was added, it was confirmed that muscle proteolysis after exercise was continuously suppressed. The same effect was confirmed when WPI was used instead of the whey protein hydrolyzate.
[0042]
(Example 1)
1375 g of erythritol, 50 g of sucrose fatty acid ester, 350 g of citric acid and 125 g of flavor are added to a mixture of amino acid nutrients composed of 600 g of sized leucine, 300 g of isoleucine, 300 g of valine, 300 g of glutamine and 1500 g of the whey protein hydrolyzate used in Test Example 1. Mixed.
[0043]
Next, a tablet containing 500 mg of KAAM in one tablet was produced using a rotary tableting machine (product name: AP-15, manufactured by Hata Iron Works) equipped with a flat punch having a diameter of 13 mm (hereinafter referred to as tablet 1).
[0044]
(Example 2)
A fluidized-bed granulator / dryer (Glatt Co., Ltd.) was prepared by blending 1375 g of erythritol with a mixture of an amino acid nutrient component comprising 600 g of sized leucine, 300 g of isoleucine, 300 g of valine, 300 g of glutamine and 1200 g of the whey protein hydrolyzate used in Test Example 1. WSG-5), and a binder solution obtained by dissolving 100 g of maltose in 1500 g of purified water was sprayed to obtain a granulated product. 40 g of sucrose fatty acid ester was added to 3660 g of the obtained granulated and dried product to obtain granules for tableting.
[0045]
Next, compression molding was performed using a rotary tableting machine (trade name: AP-15, manufactured by Hata Iron Works) equipped with a flat punch having a diameter of 15 mm to produce a tablet containing 450 mg of KAAM in one tablet (hereinafter, tablet). 2). Similarly, tablets (tablets 3, 4, and 5) were produced using hydrolysates of WPC, β-lactoglobulin concentrate, and α-lactalbumin concentrate.
[0046]
(Example 3)
Leucine 2.0 g, isoleucine 1.0 g, valine 1.0 g, glutamine 1.0 g, whey protein hydrolyzate 4.0 g used in Test Example 1, soy protein 13.5 g, chitosan 2.5 g, arginine 1.5 g, After adding 0.05 g of caffeine, 85.0 g of flour, 50.0 g of shortening, 55.0 g of granulated sugar, and 1.5 g of baking powder, 20.0 g of water, kneading the mixture to prepare a dough, molding the mixture, and then molding the mixture in a conventional manner To produce a cookie.
[0047]
【The invention's effect】
According to the present invention, there is provided an amino acid nutrition composition having a sustained recovery effect on muscle fatigue.
Claims (13)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002350200A JP4970694B2 (en) | 2002-12-02 | 2002-12-02 | Persistent muscle fatigue improver |
| TW092133820A TW200509900A (en) | 2002-12-02 | 2003-12-02 | Sustained improver of muscular fatigue |
| CA2507835A CA2507835C (en) | 2002-12-02 | 2003-12-02 | Sustained improver of muscular fatigue |
| NZ540989A NZ540989A (en) | 2002-12-02 | 2003-12-02 | Sustained improver of muscular fatigue which contains amino acids and a whey component |
| EP03776029.5A EP1567022B1 (en) | 2002-12-02 | 2003-12-02 | Sustained improver of muscular fatigue |
| AU2003283846A AU2003283846A1 (en) | 2002-12-02 | 2003-12-02 | Sustained improver of muscular fatigue |
| CNA2003801048667A CN1719984A (en) | 2002-12-02 | 2003-12-02 | Sustained improver of muscular fatigue |
| US10/537,401 US7939099B2 (en) | 2002-12-02 | 2003-12-02 | Sustained improver of muscular fatigue |
| KR1020057009889A KR101122843B1 (en) | 2002-12-02 | 2003-12-02 | Sustained improver of muscular fatigue |
| PCT/JP2003/015429 WO2004049830A1 (en) | 2002-12-02 | 2003-12-02 | Sustained improver of muscular fatigue |
| HK06102594.0A HK1082384A1 (en) | 2002-12-02 | 2006-02-27 | Sustained improver of muscular fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002350200A JP4970694B2 (en) | 2002-12-02 | 2002-12-02 | Persistent muscle fatigue improver |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004182630A true JP2004182630A (en) | 2004-07-02 |
| JP2004182630A5 JP2004182630A5 (en) | 2005-11-04 |
| JP4970694B2 JP4970694B2 (en) | 2012-07-11 |
Family
ID=32463074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002350200A Expired - Lifetime JP4970694B2 (en) | 2002-12-02 | 2002-12-02 | Persistent muscle fatigue improver |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7939099B2 (en) |
| EP (1) | EP1567022B1 (en) |
| JP (1) | JP4970694B2 (en) |
| KR (1) | KR101122843B1 (en) |
| CN (1) | CN1719984A (en) |
| AU (1) | AU2003283846A1 (en) |
| CA (1) | CA2507835C (en) |
| HK (1) | HK1082384A1 (en) |
| NZ (1) | NZ540989A (en) |
| TW (1) | TW200509900A (en) |
| WO (1) | WO2004049830A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007000985A1 (en) | 2005-06-27 | 2007-01-04 | Kyowa Hakko Kogyo Co., Ltd. | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria |
| JP2009507045A (en) * | 2005-09-09 | 2009-02-19 | マレー ゴールバーン コーオペラティブ コー リミテッド | Composition of whey growth factor extract for reducing muscle inflammation |
| JP2009539883A (en) * | 2006-06-15 | 2009-11-19 | マレー・ゴールバーン・コー−オペラティヴ・カンパニー・リミテッド | Preparations containing whey proteins and hydrolysates for enhancing muscle recovery |
| WO2010073531A1 (en) * | 2008-12-24 | 2010-07-01 | 雪印乳業株式会社 | Muscle-building agent |
| JP2010246533A (en) * | 2009-03-25 | 2010-11-04 | Terumo Corp | Total nutritional food containing branched-chain amino acid |
| JP2012105605A (en) * | 2010-11-18 | 2012-06-07 | Terumo Corp | Branched-chain amino acid containing conprehensive nutritious food |
| JP2013521779A (en) * | 2010-03-12 | 2013-06-13 | ネステク ソシエテ アノニム | Composition for masking the flavor of nutrients and method for preparing the composition |
| WO2018164251A1 (en) * | 2017-03-10 | 2018-09-13 | 株式会社明治 | Composition for improving physical strength |
| JP2020176100A (en) * | 2019-04-22 | 2020-10-29 | 株式会社明治 | Compositions for suppressing exercise-induced muscle damage |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4815752B2 (en) * | 2004-04-01 | 2011-11-16 | 味の素株式会社 | Amino acid-containing foods and drinks |
| EP1916913B1 (en) * | 2005-08-23 | 2010-11-10 | Dr. Armand Herberger | Protein composition for treating a physiologically caused, clinically normal increased need for protein |
| WO2007108530A1 (en) * | 2006-03-23 | 2007-09-27 | Kyowa Hakko Kogyo Co., Ltd. | Muscle fatigue remedy |
| US20080279966A1 (en) * | 2007-05-08 | 2008-11-13 | Ken Clement | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| US20110130637A1 (en) * | 2008-03-20 | 2011-06-02 | University Of Dundee | Protein product for modifying cardiovascular health |
| WO2009157759A1 (en) | 2008-06-23 | 2009-12-30 | N.V. Nutricia | Nutritional composition for improving the mammalian immune system |
| ES2625331T3 (en) * | 2009-12-21 | 2017-07-19 | Glanbia Nutritionals (Ireland) Ltd. | Leucine / Peptide Composition and Formulation Procedure |
| US20110217393A1 (en) | 2010-02-23 | 2011-09-08 | Grise Michel | Anti-fatigue composition |
| JP2011184314A (en) * | 2010-03-04 | 2011-09-22 | Snow Brand Milk Products Co Ltd | Muscular atrophy-preventing agent |
| US8840950B2 (en) * | 2010-05-26 | 2014-09-23 | Jacqueline M. Hibbert | Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore |
| US20140356479A1 (en) * | 2011-08-19 | 2014-12-04 | Musclepharm Corporation | Compositions and methods for use in promoting lean body mass |
| CA2925521A1 (en) | 2013-09-25 | 2015-04-02 | Pronutria Biosciences, Inc. | Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control |
| CH714189A1 (en) * | 2017-09-25 | 2019-03-29 | Omanda Ag | Process for the production of L-leucine and whey protein L-leucine for food fortification and its application. |
| CH715997A1 (en) * | 2019-03-25 | 2020-09-30 | Omanda Ag | Protein drink and dosage unit for the administration of L-leucine-enriched whey protein components as food fortification and its production. |
| DE102020102738A1 (en) | 2020-02-04 | 2021-08-05 | Albert Wionzek | Ice cream composition with proteinogenic amino acids |
| CN111296843A (en) * | 2020-03-03 | 2020-06-19 | 上海泓商生物科技有限公司 | Anti-fatigue and sports probiotics |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687782A (en) * | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
| JPH08140628A (en) * | 1994-11-28 | 1996-06-04 | Meiji Milk Prod Co Ltd | Gelled food composition |
| JPH08198748A (en) * | 1995-01-27 | 1996-08-06 | Ajinomoto Co Inc | Amino acid nutrient composition |
| JPH0920678A (en) * | 1995-06-06 | 1997-01-21 | Clintec Nutrition Co | Composition and method for medical treatment for weakening of kidney |
| JPH0923825A (en) * | 1995-07-11 | 1997-01-28 | Ajinomoto Co Inc | Nutrition composition for horse |
| WO1999049741A1 (en) * | 1998-03-31 | 1999-10-07 | Societe Des Produits Nestle S.A. | Method for providing glutamine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60186261A (en) * | 1984-03-06 | 1985-09-21 | Ajinomoto Co Inc | Solid food composition |
| US5641531A (en) * | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
| GB2335134B (en) | 1998-03-11 | 2002-06-19 | Stalplex Ltd | A beverage |
| DE29808637U1 (en) | 1998-05-13 | 1998-07-16 | ÖKOMAG net GmbH, 85283 Wolnzach | Beverage powder |
| US6051236A (en) | 1998-11-12 | 2000-04-18 | Pacifichealth Laboratories, Inc. | Composition for optimizing muscle performance during exercise |
| US6346264B1 (en) | 1999-04-27 | 2002-02-12 | International Health Products And Services Ltd. | Supplement for restoring growth hormone levels |
| CN1214729C (en) | 2001-07-20 | 2005-08-17 | 上海光明乳业股份有限公司 | Sports milk and its production method |
| US7288570B2 (en) * | 2002-12-20 | 2007-10-30 | Nutricia N.V. | Stimulation of in vivo production of proteins |
-
2002
- 2002-12-02 JP JP2002350200A patent/JP4970694B2/en not_active Expired - Lifetime
-
2003
- 2003-12-02 KR KR1020057009889A patent/KR101122843B1/en active IP Right Grant
- 2003-12-02 TW TW092133820A patent/TW200509900A/en unknown
- 2003-12-02 WO PCT/JP2003/015429 patent/WO2004049830A1/en active Application Filing
- 2003-12-02 EP EP03776029.5A patent/EP1567022B1/en not_active Expired - Lifetime
- 2003-12-02 CN CNA2003801048667A patent/CN1719984A/en active Pending
- 2003-12-02 CA CA2507835A patent/CA2507835C/en not_active Expired - Fee Related
- 2003-12-02 AU AU2003283846A patent/AU2003283846A1/en not_active Abandoned
- 2003-12-02 NZ NZ540989A patent/NZ540989A/en unknown
- 2003-12-02 US US10/537,401 patent/US7939099B2/en not_active Expired - Lifetime
-
2006
- 2006-02-27 HK HK06102594.0A patent/HK1082384A1/en not_active IP Right Cessation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687782A (en) * | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
| JPH08140628A (en) * | 1994-11-28 | 1996-06-04 | Meiji Milk Prod Co Ltd | Gelled food composition |
| JPH08198748A (en) * | 1995-01-27 | 1996-08-06 | Ajinomoto Co Inc | Amino acid nutrient composition |
| JPH0920678A (en) * | 1995-06-06 | 1997-01-21 | Clintec Nutrition Co | Composition and method for medical treatment for weakening of kidney |
| JPH0923825A (en) * | 1995-07-11 | 1997-01-28 | Ajinomoto Co Inc | Nutrition composition for horse |
| WO1999049741A1 (en) * | 1998-03-31 | 1999-10-07 | Societe Des Produits Nestle S.A. | Method for providing glutamine |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007000985A1 (en) | 2005-06-27 | 2007-01-04 | Kyowa Hakko Kogyo Co., Ltd. | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria |
| JP5112865B2 (en) * | 2005-06-27 | 2013-01-09 | 協和発酵バイオ株式会社 | Composition for preventing or treating hemoglobinuria or myoglobinuria |
| JP2013166760A (en) * | 2005-09-09 | 2013-08-29 | Murray Goulburn Co-Operative Co Ltd | Composition of whey growth factor extract for reducing muscle inflammation |
| JP2009507045A (en) * | 2005-09-09 | 2009-02-19 | マレー ゴールバーン コーオペラティブ コー リミテッド | Composition of whey growth factor extract for reducing muscle inflammation |
| US9480717B2 (en) | 2005-09-09 | 2016-11-01 | Murray Goulburn Co-Operative Co Limited | Composition of whey growth factor extract for reducing muscle inflammation |
| JP2009539883A (en) * | 2006-06-15 | 2009-11-19 | マレー・ゴールバーン・コー−オペラティヴ・カンパニー・リミテッド | Preparations containing whey proteins and hydrolysates for enhancing muscle recovery |
| US9662368B2 (en) | 2006-06-15 | 2017-05-30 | Murray Goulburn Co-Operative., Limited | Formulation comprising whey protein and hydrolysates for improving muscle recovery |
| WO2010073531A1 (en) * | 2008-12-24 | 2010-07-01 | 雪印乳業株式会社 | Muscle-building agent |
| JP2010246533A (en) * | 2009-03-25 | 2010-11-04 | Terumo Corp | Total nutritional food containing branched-chain amino acid |
| JP2013521779A (en) * | 2010-03-12 | 2013-06-13 | ネステク ソシエテ アノニム | Composition for masking the flavor of nutrients and method for preparing the composition |
| JP2016104016A (en) * | 2010-03-12 | 2016-06-09 | ネステク ソシエテ アノニム | Composition for masking nutrient flavor and production method of the composition |
| JP2012105605A (en) * | 2010-11-18 | 2012-06-07 | Terumo Corp | Branched-chain amino acid containing conprehensive nutritious food |
| WO2018164251A1 (en) * | 2017-03-10 | 2018-09-13 | 株式会社明治 | Composition for improving physical strength |
| JP2020176100A (en) * | 2019-04-22 | 2020-10-29 | 株式会社明治 | Compositions for suppressing exercise-induced muscle damage |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003283846A1 (en) | 2004-06-23 |
| KR20050089018A (en) | 2005-09-07 |
| NZ540989A (en) | 2007-06-29 |
| JP4970694B2 (en) | 2012-07-11 |
| EP1567022B1 (en) | 2013-11-20 |
| KR101122843B1 (en) | 2012-03-21 |
| CN1719984A (en) | 2006-01-11 |
| CA2507835C (en) | 2012-10-09 |
| US7939099B2 (en) | 2011-05-10 |
| WO2004049830A1 (en) | 2004-06-17 |
| US20060127492A1 (en) | 2006-06-15 |
| EP1567022A1 (en) | 2005-08-31 |
| AU2003283846A8 (en) | 2004-06-23 |
| CA2507835A1 (en) | 2004-06-17 |
| HK1082384A1 (en) | 2006-06-09 |
| TW200509900A (en) | 2005-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4970694B2 (en) | Persistent muscle fatigue improver | |
| JP2009517464A (en) | Use of protein hydrolysates that enhance the activity of glucagon-like peptide 1 | |
| TW201041524A (en) | Lipid metabolism-improving agent | |
| WO2011108692A1 (en) | Agent for preventing muscular atrophy | |
| JP2002065212A (en) | Food composition for strengthening muscle, and muscle- strengthening agent | |
| CN105579038A (en) | Amino acid composition for use in the treatment of a PDD | |
| JP2006273850A (en) | Suppression composition for lactic acid value elevation in blood, and food and drink comprising same | |
| WO2013168548A1 (en) | Food or drink | |
| AU2005302921A1 (en) | Protein hydrolysate with antidiabetic effect | |
| WO2019058609A1 (en) | Composition for promoting energy consumption | |
| JP2006219420A (en) | Antihypertensive | |
| JP2009013143A (en) | Sleep-improving composition | |
| JP5117168B2 (en) | Oral skin improving agent and skin improving food | |
| JP5041780B2 (en) | Liver disorder improving composition | |
| JP3388678B2 (en) | Immunostimulated liquid food | |
| JP2001048794A (en) | Health food and medicinal composition which contain mixture of powder originated from leaf of mulberry and powder originated from oyster and is used for treating niddm | |
| JP2009084191A (en) | Pharmaceutical composition for inhibiting appetite | |
| JP2008156344A (en) | In vivo antioxidant, food composition for in vivo antioxidation, pharmaceutical composition for in vivo antioxidation, and inhibitor for liver function disturbance, food composition for inhibition of liver function disturbance and pharmaceutical composition for inhibition of liver function disturbance | |
| JP2016210725A (en) | Malnutrition improving agent | |
| JP2005097162A (en) | Anti-fatigue composition containing glutamine peptide | |
| JPH0515339A (en) | Protein-like composition, nourishing medicine for serious stress and nourishing medicine for hepatic disease | |
| JP2001026753A (en) | Composition for prophylaxis or treatment of hypertension | |
| JP5717433B2 (en) | Bile acid adsorption composition | |
| JP2012062309A (en) | Composition for muscular increase | |
| JP5317456B2 (en) | Composition for promoting blood secretion of endogenous opioid peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050817 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050817 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050817 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20081017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090225 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090423 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090918 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091207 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100104 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120217 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120405 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150413 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4970694 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |